Literature DB >> 15908354

An RNA vaccine based on recombinant Semliki Forest virus particles expressing the Cu,Zn superoxide dismutase protein of Brucella abortus induces protective immunity in BALB/c mice.

Angel A Oñate1, Gabriel Donoso, Gustavo Moraga-Cid, Hugo Folch, Sandra Céspedes, Edilia Andrews.   

Abstract

We constructed infectious but replication-deficient Semliki Forest virus (SFV) particles carrying recombinant RNA encoding Brucella abortus Cu,Zn superoxide dismutase (SOD). The recombinant SFV particles (SFV-SOD particles) were then evaluated for their ability to induce a T-cell immune response and to protect BALB/c mice against a challenge with B. abortus 2308. Intraperitoneal injection of mice with recombinant SFV-SOD particles did not lead to the induction of SOD-specific antibodies, at least until week 6 after immunization (the end of the experiment). In vitro stimulation of splenocytes from the vaccinated mice with either recombinant Cu,Zn SOD (rSOD) or crude Brucella protein resulted in a T-cell proliferative response and the induction of gamma interferon secretion but not interleukin-4. In addition, the splenocytes exhibited significant levels of cytotoxic T-lymphocyte activity against Brucella-infected cells. The SFV-SOD particles, but not the control virus particles, induced a significant level of protection in BALB/c mice against challenge with B. abortus virulent strain 2308. These findings indicated that an SFV-based vector carrying the SOD gene has potential for use as a vaccine to induce resistance against B. abortus infections.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15908354      PMCID: PMC1111843          DOI: 10.1128/IAI.73.6.3294-3300.2005

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  52 in total

1.  Induction of cytotoxic T lymphocyte activity by immunization with recombinant Semliki Forest virus: indications for cross-priming.

Authors:  Anke Huckriede; Laura Bungener; Marijke Holtrop; Jacqueline de Vries; Barry-Lee Waarts; Toos Daemen; Jan Wilschut
Journal:  Vaccine       Date:  2004-03-12       Impact factor: 3.641

Review 2.  Pathogenesis of Brucella.

Authors:  L D Smith; T A Ficht
Journal:  Crit Rev Microbiol       Date:  1990       Impact factor: 7.624

3.  Survival of virulent and attenuated strains of Brucella abortus in normal and gamma interferon-activated murine peritoneal macrophages.

Authors:  S M Jones; A J Winter
Journal:  Infect Immun       Date:  1992-07       Impact factor: 3.441

4.  Gamma interferon production and cytotoxicity of spleen cells from mice infected with Semliki Forest virus.

Authors:  M J Blackman; A G Morris
Journal:  J Gen Virol       Date:  1984-05       Impact factor: 3.891

5.  Two-helper RNA system for production of recombinant Semliki forest virus particles.

Authors:  C Smerdou; P Liljeström
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

6.  Biological properties of RB51; a stable rough strain of Brucella abortus.

Authors:  G G Schurig; R M Roop; T Bagchi; S Boyle; D Buhrman; N Sriranganathan
Journal:  Vet Microbiol       Date:  1991-07       Impact factor: 3.293

7.  A new generation of animal cell expression vectors based on the Semliki Forest virus replicon.

Authors:  P Liljeström; H Garoff
Journal:  Biotechnology (N Y)       Date:  1991-12

8.  Effects of gamma interferon and indomethacin in preventing Brucella abortus infections in mice.

Authors:  M G Stevens; G W Pugh; L B Tabatabai
Journal:  Infect Immun       Date:  1992-10       Impact factor: 3.441

9.  Effects of cytokines on intracellular growth of Brucella abortus.

Authors:  X Jiang; C L Baldwin
Journal:  Infect Immun       Date:  1993-01       Impact factor: 3.441

10.  Membrane fusion process of Semliki Forest virus. II: Cleavage-dependent reorganization of the spike protein complex controls virus entry.

Authors:  A Salminen; J M Wahlberg; M Lobigs; P Liljeström; H Garoff
Journal:  J Cell Biol       Date:  1992-01       Impact factor: 10.539

View more
  10 in total

Review 1.  Peptide-Based Vaccines for Tuberculosis.

Authors:  Wenping Gong; Chao Pan; Peng Cheng; Jie Wang; Guangyu Zhao; Xueqiong Wu
Journal:  Front Immunol       Date:  2022-01-31       Impact factor: 7.561

2.  Progress in Brucella vaccine development.

Authors:  Xinghong Yang; Jerod A Skyberg; Ling Cao; Beata Clapp; Theresa Thornburg; David W Pascual
Journal:  Front Biol (Beijing)       Date:  2013-02-01

Review 3.  Prophylactic vaccine delivery systems against epidemic infectious diseases.

Authors:  Chao Pan; Hua Yue; Li Zhu; Guang-Hui Ma; Heng-Liang Wang
Journal:  Adv Drug Deliv Rev       Date:  2021-07-17       Impact factor: 17.873

Review 4.  The Case for Live Attenuated Vaccines against the Neglected Zoonotic Diseases Brucellosis and Bovine Tuberculosis.

Authors:  Aseem Pandey; Ana Cabello; Lavoisier Akoolo; Allison Rice-Ficht; Angela Arenas-Gamboa; David McMurray; Thomas A Ficht; Paul de Figueiredo
Journal:  PLoS Negl Trop Dis       Date:  2016-08-18

5.  Meta-Analysis and Advancement of Brucellosis Vaccinology.

Authors:  Tatiane F Carvalho; João Paulo A Haddad; Tatiane A Paixão; Renato L Santos
Journal:  PLoS One       Date:  2016-11-15       Impact factor: 3.240

6.  Development of Human Vectored Brucellosis Vaccine Formulation: Assessment of Safety and Protectiveness of Influenza Viral Vectors Expressing Brucella Immunodominant Proteins in Mice and Guinea Pigs.

Authors:  Dina Bugybayeva; Sholpan Ryskeldinova; Nadezhda Zinina; Makhpal Sarmykova; Nurika Assanzhanova; Zhailaubay Kydyrbayev; Kaissar Tabynov
Journal:  Biomed Res Int       Date:  2020-11-19       Impact factor: 3.411

7.  A new candidate vaccine for human brucellosis based on influenza viral vectors: a preliminary investigation for the development of an immunization schedule in a guinea pig model.

Authors:  Dina Bugybayeva; Zhailaubay Kydyrbayev; Nadezhda Zinina; Nurika Assanzhanova; Bolat Yespembetov; Yerken Kozhamkulov; Kunsulu Zakarya; Sholpan Ryskeldinova; Kaissar Tabynov
Journal:  Infect Dis Poverty       Date:  2021-02-16       Impact factor: 4.520

8.  Registered Influenza Viral Vector Based Brucella abortus Vaccine for Cattle in Kazakhstan: Age-Wise Safety and Efficacy Studies.

Authors:  Sholpan Ryskeldinova; Nadezhda Zinina; Zhailaubay Kydyrbayev; Bolat Yespembetov; Yerken Kozhamkulov; Dulat Inkarbekov; Nurika Assanzhanova; Aigerim Mailybayeva; Dina Bugybayeva; Makhpal Sarmykova; Berik Khairullin; Kairat Tabynov; Aitbay Bulashev; Batyrbek Aitzhanov; Khairulla Abeuov; Abylay Sansyzbay; Tlektes Yespolov; Gourapura J Renukaradhya; Steven Olsen; Angel Oñate; Kaissar Tabynov
Journal:  Front Cell Infect Microbiol       Date:  2021-07-01       Impact factor: 5.293

9.  Characterization of recombinant B. abortus strain RB51SOD toward understanding the uncorrelated innate and adaptive immune responses induced by RB51SOD compared to its parent vaccine strain RB51.

Authors:  Jianguo Zhu; Charles B Larson; Megan Ann Ramaker; Kimberly Quandt; Jered M Wendte; Kimberly P Ku; Fang Chen; George W Jourdian; Ramesh Vemulapalli; Gerhardt G Schurig; Yongqun He
Journal:  Front Cell Infect Microbiol       Date:  2011-11-25       Impact factor: 5.293

Review 10.  A history of the development of Brucella vaccines.

Authors:  Eric Daniel Avila-Calderón; Ahidé Lopez-Merino; Nammalwar Sriranganathan; Stephen M Boyle; Araceli Contreras-Rodríguez
Journal:  Biomed Res Int       Date:  2013-06-03       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.